Elizabeth Scott's questions to SELB leadership • Q3 2022
Question
Elizabeth Scott of SVB Securities inquired about the expectations for the upcoming SEL-212 Phase III readout, specifically the anticipated serum uric acid response rate, anti-drug antibody mitigation, and any available data on discontinuation rates.
Answer
President and CEO Carsten Brunn expressed confidence, citing prior Phase II trials that showed response rates in the mid-60% range. He clarified that the primary endpoint is serum uric acid (SUA) levels at Month 6, not anti-drug antibodies (ADAs). Brunn noted the company is blinded to the Phase III discontinuation rates and will report top-line data in Q1 2023.